Actavia Life Sciences IncOTC Pink - Current Information:RASP
- LAST PRICE0.0078
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.0080/ 100
- Ask / Lots0.0176/ 200
- Open / Previous Close0.0000 / 0.0078
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Actavia Life Sciences Inc | 6.0M | -1.0x | --- |
ProtoKinetix Inc | 6.0M | -15.0x | --- |
Protagenic Therapeutics Inc | 6.1M | -1.2x | --- |
Avenue Therapeutics Inc | 6.0M | -0.1x | --- |
HST Global Inc | 5.9M | -40.2x | --- |
Kazia Therapeutics Ltd | 9.1M | -0.5x | --- |
Company Information
Actavia Life Sciences, Inc. is a leukemia-focused biotechnology company. The Company is engaged in developing therapeutics to address the unmet need that exists for acute myeloid leukemia (AML), and other forms of leukemia and lymphoma. AML is generally a disease of older adults. It develops small molecule drug candidates targeting the LSD1 gene, which controls pathways underlying the etiology of AML subtypes. Its RASP-201 is a novel, orally dosed, selective reversible inhibitor of lysine specific demethylase (LSD1), a pathway that blocks differentiation and confers a poor prognosis to AML. RASP-201 when dosed orally shows in vivo therapeutic utility in murine (mouse) models of AML. Its primary indication is AML which may be fatal within weeks to months.
Contact Information
- Headquarters
- 420 Lexington Ave Ste 2525NEW YORK, NY, United States 10170-2599
- Phone
- 646-396-4087
- Fax
- ---
Executives
- Independent Chairman of the Board
- Willy Simon
- Finance Director
- Keeren Shah
- Independent Director
- John Brancaccio
- Independent Director
- Gary Jacob
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $6.0M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 771.8M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | --- |
EPS | $-0.01 |
Book Value | $0.00 |
P/E Ratio | -1.0x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
